Exact Sciences announced that the Nancy Gardner Sewell Medicare Multi‑Cancer Early Detection Screening Coverage Act was signed into law on February 3 2026, establishing a Medicare reimbursement pathway for blood‑based multi‑cancer early detection (MCED) tests once they receive FDA approval and CMS implementation.
The legislation creates a clear payment framework for Exact Sciences’ Cancerguard test, which is currently a laboratory‑developed test (LDT) and is still undergoing clinical evaluation. The act does not grant immediate coverage; Medicare will begin reimbursing the test only after FDA clearance and a CMS implementation schedule that is expected to follow the agency’s standard review timeline. The new pathway unlocks an estimated $25 billion addressable market for MCED tests, a figure that reflects the proportion of U.S. cancer cases that lack recommended screening and the potential volume of Medicare beneficiaries who could benefit.
Exact Sciences’ recent financial performance underscores the strategic importance of this regulatory win. In Q3 2025 the company generated $851 million in revenue, a 20% year‑over‑year increase, and reported a net loss of $20 million, a narrowing loss that signals progress toward profitability. The prior quarter, Q4 2024, saw revenue of $713 million, up 10% YoY, indicating steady growth across its core product lines, including the stool‑based Cologuard and the Oncotype DX assay.
Kevin Conroy, Exact Sciences’ chairman and CEO, said the legislation “is a historic day in the fight against cancer” and highlighted the potential for the new coverage to give patients “more opportunities to celebrate birthdays, anniversaries, and precious moments.” Conroy added that the act “deepens our commitment to early detection and expands the reach of our blood‑based platform to the largest payer in the country.”
Analysts and investors reacted positively to the passage, citing the removal of a major reimbursement barrier as a key driver of future revenue growth. The announcement also dovetails with the company’s pending acquisition by Abbott Laboratories, which is expected to close in the second quarter of 2026 and will further strengthen Exact Sciences’ commercial reach and capital resources.
The competitive landscape for MCED is intensifying, with companies such as Freenome also developing blood‑based tests. Exact Sciences’ early mover advantage, combined with the new Medicare pathway, positions it to capture a larger share of the expanding diagnostics market. The company will now focus on accelerating FDA submission, engaging with CMS to finalize implementation timelines, and scaling its commercial operations to meet the anticipated demand from Medicare beneficiaries.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.